Latest Interviews

How Surbhi Sarna Built A $275M Biotech Company From Nothing

Surbhi Sarna, Ryan Briggs

Serby Serna founded Envision Medical to develop the first FDA-cleared device for early ovarian cancer detection, overcoming significant investor bias by securing seed funding before raising $20 million to advance the technology. The company achieved a $275 million acquisition by Boston Scientific after demonstrating clinical viability, marking a successful exit for Serna who previously faced rejections based on her lack of advanced degrees. Now a Group Partner at Y Combinator, Serna leverages her experience to advocate for biotech founders based on problem-solution fit rather than traditional academic credentials.

All-In Summit: Jenny Just on Peak6, the female market correction, poker, and risk

Jenny Just, Chamath, Calacanis, Friedberg

Jenny, founder of the multi-billion dollar financial services firm Peak Six, leveraged her company's century-long trading track record to advocate for bridging the gender gap in finance through strategic risk-taking. She launched the "Poker Power" initiative to teach probability and capital allocation to millions of women, aiming to normalize early risk exposure and dismantle the confidence gap that hinders female participation. With Peak Six currently holding record inventory in anticipation of a volatility-driven market correction, the firm combines its "long volatility" investment thesis with a broader mission to reshape the industry's demographic landscape over the next five years.

Spotify Founder: How A 23 Year Old Introvert Built A $31 Billion Business!

Whitney Wolfe Herd, Daniel Ek

Spotify co-founder Daniel Ek details the high-stakes journey of transforming a bankrupt music industry into a $50 billion entity by leveraging his generalist strengths and relying on a stabilizing partnership with co-founder Martin Lorentzon. Facing near-death financial crises and personal physical tolls during two years of licensing negotiations, Ek navigated competition from tech giants like Apple through strategic focus on cross-platform ubiquity and superior personalization algorithms. The narrative concludes with Ek's evolved leadership philosophy, which prioritizes a culture of calculated risk-taking and self-directed learning over traditional specialist expertise to guide the company's expansion into podcasting and audio content.

Longevity: can ageing be reversed?

Experts project that treatments to reverse biological age could emerge within five decades, driven by breakthroughs such as epigenetic reprogramming and genetic interventions like those modifying the *DAF2* gene. These scientific advances, supported by studies on dietary restriction and the health benefits of centenarians, are attracting significant capital to develop therapies targeting senescent cells and common drugs like Metformin. The resulting economic imperative aims to reduce the burden of age-related disease while transforming the demographic challenge of an aging population into a trillions-of-dollars opportunity.

All-In Summit: AI film and the generative art revolution with Caleb Ward

Caleb Ward, Wes Anderson, Chamath, Calacanis, Friedberg, David Sacks

Caleb Ward, CEO of Curious Refuge, demonstrates how current generative AI tools can independently produce scripts, visuals, and audio for film within hours for under $10, though human curation remains essential for narrative coherence. By transitioning from training VFX studios to a global bootcamp, his organization is enabling diverse creators ranging from Academy Award winners to young students to integrate these hybrid workflows into professional pipelines. Ward predicts a future shift toward personalized "prompt-to-media" content, emphasizing that while technical barriers are lowering, the critical challenge lies in parameterizing human creative decision-making to solve for emotional resonance.

All-In Summit: In conversation with Vinod Khosla

Vinod Khosla, Chamath, Calacanis, Friedberg

Khosla Ventures founder Vinod Khosla, drawing on a career managing Sun Microsystems and achieving massive returns in networking firms, criticizes conventional venture capital for prioritizing short-term recaps over the brutal honesty required to build foundational innovations. He outlines a strategic shift toward investing in alternative AI methodologies and hard tech like Helion Energy's fusion architecture, arguing that long-term fundamental value persists despite market volatility. Looking twenty-five years ahead, Khosla predicts the obsolescence of traditional work necessitating a societal redefinition of human purpose and potential economic models like Universal Basic Income to manage displacement and reduce income disparity.

All-In Summit: Gene therapy and a new era of medicine with Dr. Nicole Paulk

Dr. Nicole Paulk, Chamath, Calacanis, Friedberg

Dr. Nicole Paul's Siren Biotechnology is transitioning from stealth to clinical trials with a universal AAV platform designed to treat cancer by engineering viral logic circuits that reactivate immune surveillance against invisible tumors. Preclinical data demonstrates functional cures in human brain cancer models, positioning the company to launch its first trial in 2025 despite facing significant industry headwinds including manufacturing bottlenecks and restrictive FDA regulations. While the immediate focus remains on oncology, the technology aims to eventually enable human augmentation and longevity applications, contingent upon future regulatory shifts regarding non-disease therapeutic targets.

Universally Accessible Intelligence with Character.ai's Noam Shazeer

Noam Shazeer, Sarah Wang

Co-founder Noam Shazeer details Character.ai's vertically integrated strategy to accelerate AGI development by prioritizing generalizable dialogue models over domain-specific applications, a choice that has driven over 20 billion messages and sustained two hours of daily engagement per user. The company leverages current scaling laws to rapidly reduce training costs while projecting a model tens of IQ points smarter by year-end alongside multimodal enhancements like voice and long-term memory. Shazeer frames the technology as a pre-AGI breakthrough comparable to the Wright Brothers' first flight, predicting ubiquitous, affordable intelligence within a year as global H100 infrastructure expands, while dismissing immediate existential risks in favor of a four-month pause for safety verification.

Democratizing Design with Figma's Dylan Field

Dylan Field, David George

Figma is redefining the design industry by integrating AI agents like JamBot to transform linear workflows into non-linear exploration, effectively collapsing traditional boundaries between design and development roles. While the company acknowledges that foundational models are trending toward commoditization, it leverages its unique abstract syntax tree to position its platform as a critical bridge from "systems of record" to predictive and actionable interfaces. This strategic pivot aims to accelerate product cycles by lowering the barrier to entry for broader teams while maintaining human judgment as the essential differentiator for final production quality.

AI Copilots and the Future of Knowledge Work with Microsoft's Kevin Scott

Kevin Scott, Bob Swan

Microsoft positions artificial intelligence as a foundational platform rivaling the personal computer, driving a strategic ecosystem of partners like OpenAI, GitHub, and Meta to build unanticipated applications. The company addresses hardware scarcity and operational scaling to enable rapid deployment of models like Llama 2, aiming to trigger an industrial revolution in cognitive work by mitigating talent deficits and eliminating drudgery. Internal metrics prioritize user flow and value delivery over code volume, while leadership encourages entrepreneurs to tackle complex problems by leveraging AI as infrastructure rather than a standalone product.

Leveling Up with Roblox's David Baszucki

David Baszucki, Jonathan Lai

Roblox is redefining its platform as a primary medium for long-distance human communication by integrating AI across invisible infrastructure, generative creation tools, and future general intelligence. The company is developing proprietary multimodal models to enable text-driven 3D generation and dynamic virtual agents while optimizing its massive server infrastructure to support high-volume inference for millions of co-creators. Strategic shifts include re-evaluating discovery algorithms for long-term value and expanding mobile and VR compatibility, as evidenced by the MetaQuest app's rapid user adoption.

AI Food Fights in the Enterprise with Databricks' Ali Ghodsi

Ali Ghodsi, Ben Horowitz

Enterprise leaders are bypassing traditional IT hierarchies to directly leverage generative AI as a competitive advantage, though adoption remains hindered by organizational friction, data privacy concerns, and the high cost of infrastructure. Organizations are navigating a strategic fork between training proprietary models for specialized tasks and relying on generalist foundations, while open-source releases accelerate innovation despite GPU scarcity. While benchmarks and ethical debates continue, the industry trajectory points toward architectural efficiency and specific vertical applications rather than immediate superintelligence threats.

Where We Go From Here with OpenAI's Mira Murati

Mira Murati, Martin Casado

Former Tesla engineer and OpenAI speaker leveraged a background in mathematics and physics to help shape the development of ChatGPT, transforming a research alignment tool into a widely adopted product through Reinforcement Learning from Human Feedback. By releasing models via public APIs, the initiative accelerated the discovery of emergent use cases while addressing critical challenges like hallucinations and the shift from finite-state programming to natural language collaboration. Looking ahead, OpenAI focuses on scaling capabilities toward artificial general intelligence and establishing dedicated teams to solve super-alignment, ensuring future systems can reliably perform human intellectual work.

Digital Biology with insitro's Daphne Koller

Daphne Koller, Vijay Pande

In-Citro, founded by Coursera co-creator Daphne Koller, is deploying a "data factory" model that uses CRISPR-edited human pluripotent stem cells to systematically generate genetic variance data for drug discovery. The company's proprietary POSH platform and multimodal biology language models analyze hundreds of millions of cells to identify disease mechanisms and predict therapeutic interventions, effectively replacing error-prone murine testing with human-derived systems. Koller aims to deliver a first tranche of medicines to patients by the end of the decade while extending this digital biology framework to address global challenges in agriculture and environmental sustainability.

Improving AI with Anthropic's Dario Amodei

Dario Amodei, Anjney Midha

Anthropic CEO Dario Amodei outlines a strategy centered on scaling laws that project model costs reaching $10 billion by 2025 while emphasizing a "talent density" hiring philosophy that prioritizes physicists and generalists over domain specialists. The organization implements Constitutional AI to replace human feedback with codified principles derived from global standards like the UN Declaration, enabling safer, self-correcting systems that balance capability growth with safety gates comparable to aviation protocols. Future product roadmaps leverage massive context windows for complex reasoning tasks, supported by mathematical projections that predict stable inference costs for the next three to four years despite increasing model size.